Symbicort in Chronic Obstructive Pulmonary Disease (SYMBOL)

AstraZeneca

Status: Completed

Conditions: Chronic Obstructive Pulmonary Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT00611520

1312005009

Details and patient eligibility

About

Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. pneumologists and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.

Enrollment: 64,730 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with COPD treated with budesonide/formoterol

Exclusion criteria

• limitations; possible risks; warnings; contraindications mentioned in the SPC.

Trial design

64,730 participants in 1 patient group

1

Description:

Patients with COPD treated with budesonide/formoterol